IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)
Background Guselkumab is an interleukin (IL)-23 pathway blocker with proven efficacy in patients with moderate-to-severe plaque psoriasis. Early intervention with guselkumab may result in changes to the clinical disease course versus later intervention. - Methods and analysis Here we present the rat...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
September 13, 2021
|
| In: |
BMJ open
Year: 2021, Jahrgang: 11, Heft: 9, Pages: 1-10 |
| ISSN: | 2044-6055 |
| DOI: | 10.1136/bmjopen-2021-049822 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1136/bmjopen-2021-049822 Verlag, lizenzpflichtig, Volltext: https://bmjopen.bmj.com/content/11/9/e049822 
|
| Verfasserangaben: | Kilian Eyerich, Peter Weisenseel, Andreas Pinter, Knut Schäkel, Khusru Asadullah, Sven Wegner, Ernesto J. Muñoz-Elias, Holger Bartz, Friedmann J.H. Taut, Kristian Reich |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1777282381 | ||
| 003 | DE-627 | ||
| 005 | 20250103000425.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211111s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmjopen-2021-049822 |2 doi | |
| 035 | |a (DE-627)1777282381 | ||
| 035 | |a (DE-599)KXP1777282381 | ||
| 035 | |a (OCoLC)1341423961 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Eyerich, Kilian |d 1979- |e VerfasserIn |0 (DE-588)133076814 |0 (DE-627)533325765 |0 (DE-576)299606821 |4 aut | |
| 245 | 1 | 0 | |a IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis |b rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE) |c Kilian Eyerich, Peter Weisenseel, Andreas Pinter, Knut Schäkel, Khusru Asadullah, Sven Wegner, Ernesto J. Muñoz-Elias, Holger Bartz, Friedmann J.H. Taut, Kristian Reich |
| 264 | 1 | |c September 13, 2021 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 11.11.2021 | ||
| 520 | |a Background Guselkumab is an interleukin (IL)-23 pathway blocker with proven efficacy in patients with moderate-to-severe plaque psoriasis. Early intervention with guselkumab may result in changes to the clinical disease course versus later intervention. - Methods and analysis Here we present the rationale and design of a phase 3b, randomised, double-blind, multicentre study (GUIDE), comparing treatment effects of guselkumab in patients with short (≤2 years) or longer (>2 years) duration of plaque-type psoriasis, measured from first appearance of psoriatic plaques. Participants achieving skin clearance (Psoriasis Area and Severity Index (PASI)=0) by week 20 and maintaining complete clearance at week 28 visit (‘super-responders’ (SRe)) will be randomised to continue approved maintenance dosing every 8 weeks (q8w) versus an investigational maintenance dosing interval of 16 weeks (q16w) until week 68. Primary endpoint: proportion of participants in the q8w vs q16w arms with absolute PASI <3 at week 68. Participants with PASI <3 at week 68 will be withdrawn from guselkumab treatment for up to 48 weeks. Participants not achieving SRe criteria (non-SRe) will remain in the study with q8w guselkumab dosing through week 68. Additional to serum samples obtained from all patients, skin biopsies and whole-blood samples will be taken from SRe and non-SRe participants at various time points in optional substudies. Analyses include: genetics; immunophenotyping (fluorescence-activated cell sorting); gene and protein expression profiling; immunohistology. By merging clinical endpoints with mechanistic findings, this study aims to elucidate how IL-23 blockade with guselkumab can modify the disease course by altering molecular and cellular drivers that cause relapse after treatment withdrawal, particularly among SRe. - Ethics and dissemination Approval obtained from ethics committee Medical Council Hamburg, Germany (PVN5925). GUIDE is compliant with the Declaration of Helsinki. - Trial registration number Registered at ClinicalTrials.gov (NCT03818035). All primary endpoint results (prespecified analyses) will be submitted to peer-reviewed, international journals within 18 months after primary completion date. | ||
| 650 | 4 | |a adult dermatology | |
| 650 | 4 | |a protocols & guidelines | |
| 650 | 4 | |a psoriasis | |
| 700 | 1 | |a Weisenseel, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |8 1\p |a Pinter, Andreas |d 1979- |e VerfasserIn |0 (DE-588)1071806246 |0 (DE-627)826332099 |0 (DE-576)433308338 |4 aut | |
| 700 | 1 | |a Schäkel, Knut |e VerfasserIn |0 (DE-588)1032757418 |0 (DE-627)739272896 |0 (DE-576)251064476 |4 aut | |
| 700 | 1 | |8 2\p |a Asadullah, Khusru |d 1967- |e VerfasserIn |0 (DE-588)121864855 |0 (DE-627)081585055 |0 (DE-576)292925697 |4 aut | |
| 700 | 1 | |8 3\p |a Wegner, Sven |e VerfasserIn |0 (DE-588)140451951 |0 (DE-627)618396837 |0 (DE-576)318168375 |4 aut | |
| 700 | 1 | |a Muñoz-Elias, Ernesto J. |e VerfasserIn |4 aut | |
| 700 | 1 | |8 4\p |a Bartz, Holger |d 1972- |e VerfasserIn |0 (DE-588)171933389 |0 (DE-627)69682471X |0 (DE-576)132811723 |4 aut | |
| 700 | 1 | |a Taut, Friedmann J. H. |e VerfasserIn |4 aut | |
| 700 | 1 | |8 5\p |a Reich, Kristian |e VerfasserIn |0 (DE-588)113916019 |0 (DE-627)618892729 |0 (DE-576)318566702 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ open |d London : BMJ Publishing Group, 2011 |g 11(2021), 9, Artikel-ID e049822, Seite 1-10 |h Online-Ressource |w (DE-627)654747075 |w (DE-600)2599832-8 |w (DE-576)339269340 |x 2044-6055 |7 nnas |a IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE) |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:9 |g elocationid:e049822 |g pages:1-10 |g extent:10 |a IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE) |
| 856 | 4 | 0 | |u https://doi.org/10.1136/bmjopen-2021-049822 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://bmjopen.bmj.com/content/11/9/e049822 |x Verlag |z lizenzpflichtig |3 Volltext |
| 883 | |8 1\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 2\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 3\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 4\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 883 | |8 5\p |a cgwrk |d 20241001 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | ||
| 951 | |a AR | ||
| 992 | |a 20211111 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 1032757418 |a Schäkel, Knut |m 1032757418:Schäkel, Knut |d 910000 |d 911300 |e 910000PS1032757418 |e 911300PS1032757418 |k 0/910000/ |k 1/910000/911300/ |p 4 | ||
| 999 | |a KXP-PPN1777282381 |e 4001620545 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"September 13, 2021"}],"id":{"doi":["10.1136/bmjopen-2021-049822"],"eki":["1777282381"]},"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"given":"Kilian","family":"Eyerich","display":"Eyerich, Kilian","role":"aut"},{"role":"aut","family":"Weisenseel","display":"Weisenseel, Peter","given":"Peter"},{"given":"Andreas","family":"Pinter","display":"Pinter, Andreas","role":"aut"},{"role":"aut","given":"Knut","display":"Schäkel, Knut","family":"Schäkel"},{"role":"aut","family":"Asadullah","display":"Asadullah, Khusru","given":"Khusru"},{"family":"Wegner","display":"Wegner, Sven","given":"Sven","role":"aut"},{"given":"Ernesto J.","family":"Muñoz-Elias","display":"Muñoz-Elias, Ernesto J.","role":"aut"},{"given":"Holger","family":"Bartz","display":"Bartz, Holger","role":"aut"},{"role":"aut","display":"Taut, Friedmann J. H.","family":"Taut","given":"Friedmann J. H."},{"role":"aut","family":"Reich","display":"Reich, Kristian","given":"Kristian"}],"title":[{"subtitle":"rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)","title":"IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis","title_sort":"IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis"}],"physDesc":[{"extent":"10 S."}],"relHost":[{"disp":"IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)BMJ open","pubHistory":["2011 -"],"recId":"654747075","note":["Gesehen am 02.10.20"],"language":["eng"],"id":{"issn":["2044-6055"],"zdb":["2599832-8"],"eki":["654747075"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"dateIssuedDisp":"2011-","publisherPlace":"London","dateIssuedKey":"2011","publisher":"BMJ Publishing Group"}],"part":{"text":"11(2021), 9, Artikel-ID e049822, Seite 1-10","pages":"1-10","volume":"11","issue":"9","extent":"10","year":"2021"},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"BMJ open","title":"BMJ open"}]}],"name":{"displayForm":["Kilian Eyerich, Peter Weisenseel, Andreas Pinter, Knut Schäkel, Khusru Asadullah, Sven Wegner, Ernesto J. Muñoz-Elias, Holger Bartz, Friedmann J.H. Taut, Kristian Reich"]},"note":["Gesehen am 11.11.2021"],"recId":"1777282381"} | ||
| SRT | |a EYERICHKILIL23BLOCKA1320 | ||